Vaccine Effectiveness Data News Today

It shows that after you get that third immunization, whereas it was, you know, reinstalling 90%, 95% protection versus the previous lineages, its around 70% to 75% against omicron. still pretty good and much better against hospitalizations. but against symptomatic infections, 70%, 75%. the problem is its not holding up. it seems to be going down quickly after two or three months, down to maybe 30% to 40% according to imperial college. the idea for the fourth immunization, again, is another way t...

Designers of the patentless vaccine, which has just been granted emergency use authorization in india. we want to talk about that, dr. hotez. that is incredibly significant news. but first i would like to get your reaction to this new johnson & johnson report. >> well, you know, kaitlan, this was actually always a good vaccine. the j&j vaccine is an outstanding vaccine. if you give it in two doses. i think whats happened here in the united states is there are a lot of circumstances that cause pe...

To weigh whether a faction eshould be released to certain populations? does it make sense to just take j&j off the payable? >> as i sake to say. it doesnt take much even for a good vaccine to be taken off the market because of public perception and it took two fits. one is the fact that almost of our vaccine effectiveness data is coming out of the criminal and the uk and the vaccine is not used in those two din industries from. they havent happy with had a they got and then the cdc throws

>> theres a possibility. in fairness to johnson & johnson, for pfizer, we had the data for vaccine effectiveness coming out of israel and the uk. thats what really i think helped push this over the edge with the fda. moderna and johnson & johnson are not used in those countries. we havent really collected vaccine effectiveness data as much as we would like. its a good vaccine. but there are deficiency in the packet. theres misunderstanding about the paper that came out yesterday in terms of john...

Data, the johnson & johnson vaccine as a two dose vaccine is still very good. >> how comfortable -- i know that pfizer, moderna, johnson & johnson have good scientific reputations. that said, how comfortable are you that we are relying on their data sets, their collection of data? shouldnt this be done independently? shouldnt we be asking maybe its another academic institution, but shouldnt we collect the data on the vaccines that way? >> typically it would be a combination of the two. there wou...

Ministry of health. we have a powerpoint slide coming from pfizer shareholder meeting. this is not the way to do science. were getting it from press releases, so hopefully well get some clarity. what the publicly available data show is that there has been a decline in the protection against infection, meaning it went over from 90%, 95% to 40% to 50% for the pfizer vaccine, a significant decline. what we havent seen is evidence of a lot of breakthrough hospitalizations, and maybe thats going to b...